Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Université du Québec à Rimouski | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Determine whether personal optimization of the Omega-3 index improves cellular metabolism and quality of life (according to the SF-36 form).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MAG-EPA | Experimental | MAG-EPA softgel (500mg), daily dose between 1g and 3.5g |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MAG-EPA | Dietary Supplement | Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8. |
| Measure | Description | Time Frame |
|---|---|---|
| Omega-3 Index | Achievement of an omega-3 index of 8. | 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Cellular metabolism | To determine whether the achievement of the optimal level of the omega-3 index results in an improvement in the white blood cell energy metabolism | 8 weeks |
| Quality of life |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Anne-Julie Landry, MSc | SCF Pharma | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SCF Pharma | Rimouski | Quebec | G5M 1J5 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C588285 | 1-eicosapentaenoylglycerol |
Not provided
Not provided
Not provided
Prospective, single arm trial where each participant receives a personalized dose
Not provided
Not provided
Not provided
Not provided
Determine whether the achievement of the optimal level of the Omega-3 index results in an improvement in quality of life (according to Form SF-36)
| 8 weeks |
| Heart rate | Confirm the link between the optimal omega-3 index and heart rate (bpm) | 8 weeks |
| Total Cholesterol | Confirm the link between the optimal omega-3 index and total cholesterol (in mmol/L) | 8 weeks |
| Triglycerides | Confirm the link between the optimal omega-3 index and triglycerides level (in mmol/L) | 8 weeks |
| HDL-cholesterol | Confirm the link between the optimal omega-3 index and HDL-cholesterol (in mmol/L) | 8 weeks |
| LDL-cholesterol | Confirm the link between the optimal omega-3 index and LDL-cholesterol (in mmol/L) | 8 weeks |
| Alanine aminotransferase | Confirm the link between the optimal omega-3 index and alanine aminotransferase (in U/L | 8 weeks |
| Aspartate aminotransferase | Confirm the link between the optimal omega-3 index and aspartate aminotransferase (in U/L) | 8 weeks |
| Bilirubin | Confirm the link between the optimal omega-3 index and Bilirubin (in µmol/L) | 8 weeks |
| Albumin | Confirm the link between the optimal omega-3 index and Albumin (in g/L) | 8 weeks |
| C-reactive protein | Confirm the link between the optimal omega-3 index and C-reactive protein (in mg/L) | 8 weeks |
| Apolipoprotein B | Confirm the link between the optimal omega-3 index and Apolipoprotin B (in mmol/L) | 8 weeks |
| Erythrocyte sedimentation rate | Confirm the link between the optimal omega-3 index and the erythrocyte sedimentation rate (in min) | 8 weeks |
| Systolic blood pressure | Confirm the link between the optimal omega-3 index and the systolic blood pressure (in mm Hg) | 8 weeks |
| Diastolic blood pressure | Confirm the link between the optimal omega-3 index and the diastolic blood pressure (in mm Hg) | 8 weeks |